This innovative product is the first ready-to-infuse formulation of vancomycin, designed to simplify and speed up treatment for serious bacterial infections.
The company secured European Union Medical Device Regulation (EU MDR) certification for its iStent platform, including the iStent infinite and iStent inject W devices.
This report builds on previous findings but highlights that much crucial information needed to understand how the virus emerged fully is still missing.
Mounjaro was first launched in India in late March 2025, initially available only in 2.5 mg and 5 mg vial forms.
This recommendation is a crucial milestone, as no treatment for MASH is currently approved in the European Union.
The approval of AVT06 follows a growing trend of biosimilars entering the market after Bayer’s patent expiry.
The new approval expands its use to earlier stages of the disease, aiming to reduce the risk of recurrence and improve long-term outcomes for patients.
These models position midwives as the primary caregivers for women and babies throughout pregnancy, childbirth, and the postnatal period, promoting a more personalized and supportive approach to maternal and newborn health.
Yeztugo’s twice-yearly injection aims to overcome these obstacles by reducing the frequency of dosing and potentially lowering stigma associated with daily medication.
Women with sickle cell disease management (SCD) are four to eleven times more likely to die during pregnancy compared to those without the disease.